source
- Amgen’s Repatha linked to fewer heart attacks while Novartis reports seven new tumor cases in Zolgensma patientsAmgen reported that its cholesterol‑lowering drug Repatha was associated with a lower incidence of heart attacks in a recent analysis. The data suggest the therapy may provide cardiovascular benefi…
- Agios cuts over 35% of R&D staff as FDA decision on sickle cell drug is delayedAgios announced it will eliminate more than 100 R&D positions, representing over a third of its research staff, after the FDA postponed a decision on its sickle cell disease candidate. The company…